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DRUG EVALUATION
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ABSTRACT
Introduction: The overall survival of patients with multiple myeloma has improved with the advent of 
novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents 
such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increas-
ingly used in earlier lines of therapy. Patients with disease that is refractory to multiple novel agents 
represent a population with high unmet medical need and for whom therapies with new mechanisms 
of action could be beneficial. Melphalan flufenamide (melflufen) has demonstrated encouraging activity 
in patients with relapsed and refractory multiple myeloma.
Areas covered: This review provides an overview of the mechanism of action of melflufen, a first-in-class 
peptide-drug conjugate that targets aminopeptidases and rapidly delivers alkylating agents into tumor 
cells. It reviews key Phase I and II clinical trial data for melflufen in combination with dexamethasone as well 
as in triplet combinations with daratumumab or bortezomib. The safety profile of melflufen, which is 
characterized primarily by clinically manageable hematologic adverse events, is described.
Expert opinion: Melflufen has potential to fill a gap in the myeloma treatment landscape by providing 
a new mechanism of action with clinically meaningful efficacy and a favorable safety profile in patients 
refractory to multiple novel agents.
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Multiple myeloma (MM), is a plasma cell neoplasia, characterized 
by an abnormal proliferation of aberrant plasma cells in the bone 
marrow and the production of a clonal immunoglobulin [1]. 
Median age at diagnosis is 69 years with a third of patients diag-
nosed over the age of 75 years [2]. MM is associated with bone 
lesions and fractures, infections, and end-organ damage [1,3]. 
Despite new treatment options that have improved outcomes 
for patients with MM, the disease remains incurable [4,5]. 
Approved and commonly used treatments for MM include immu-
nomodulatory drugs (IMiDs), proteasome inhibitors, alkylators, and 
monoclonal antibodies (mAbs) [6–10]. In addition, histone deace-
tylase inhibition using panobinostat in combination with bortezo-
mib and dexamethasone as well as IMiDs confers meaningful 
clinical benefit in the relapsed and refractory setting [11–13]. 
Currently, patients who relapse after receiving prior IMiDs, protea-
some inhibitors, anti-CD38 mAbs such as daratumumab, and anti- 
signaling lymphocytic activation molecule F7 (SLAMF7) mAbs such 
as elotuzumab have limited treatment options [14]. The combina-
tion of agents with distinct mechanisms of action (MOAs) has the 
potential to enhance efficacy and overcome resistance 
mechanisms by exerting complementary antimyeloma effects 
[5,15]. Chemotherapy has historically been a mainstay of treat-
ment, but aside from melphalan as a conditioning agent prior to 
transplant or the use of alkylator-based regimens in older patients 
in certain regions, chemotherapy usage is decreasing based on the 
superiority of novel targeted agents [6,16]. Melphalan flufenamide 
(melflufen) is a first-in-class peptide-drug conjugate (PDC) being 
evaluated in clinical trials in patients with relapsed/refractory MM 
(RRMM, Box 1) [17–20]. Agents such as melflufen with distinct 
MOAs are needed to address growing unmet needs in RRMM.
1.1. Unmet needs in RRMM
In the last decade, combinations based on IMiDs, proteasome 
inhibitors, anti-CD38 mAbs such as daratumumab, and anti- 
SLAMF7 mAbs such as elotuzumab have significantly 
improved outcomes and prolonged survival in patients with 
MM [21–25]. In the frontline setting, new combination strate-
gies with anti-CD38 mAbs have shown clinical benefit, includ-
ing triplet and quadruplet regimens that contain IMiDs, 
proteasome inhibitors, and steroids to complement older 
modalities of therapy and stem cell transplant [26,27]. While 
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these combinations have potential to further improve patient 
outcomes, their use in frontline can result, at relapse, in 
patients with disease that is refractory to several drugs with 
different MOAs. Moreover, the choice of second-line treatment 
is largely dependent on prior therapy and prior response to 
therapy, and a class switch is often prioritized [28,29].
MM is characterized by the emergence of therapy-resistant 
clones driven by selective pressure of treatment throughout the 
disease course [4,5,27]. Patients with RRMM with disease refrac-
tory to multiple novel agents represent a population with high 
unmet medical need and limited effective treatment options as 
well as poor outcomes. In the retrospective MAMMOTH study, 
275 patients with RRMM refractory to an anti-CD38 mAb had 
received a median of four and a maximum of 16 lines of therapy 
[30]. Survival was dismal overall and for the subgroups of ‘not 
triple-refractory’ (refractory to 1 anti-CD38 mAb and not both of 
a proteasome inhibitor and an IMiD), ‘triple- and quad- 
refractory’ (refractory to 1 anti-CD38 mAb plus 1 proteasome 
inhibitor or IMiD plus 1 or 2 therapies of the other class), and 
‘penta-refractory’ (refractory to 1 anti-CD38 mAb plus 2 protea-
some inhibitors plus 2 IMiDs) patients. Median overall survival 
(OS) was 8.6 months for all patients, 11.2 months for patients 
who were not triple-refractory, 9.2 months for those with triple- 
or quadruple-refractory disease, and 5.6 months for those with 
penta-refractory disease. Similarly, poor survival outcomes for 
patients refractory to an IMiD and a proteasome inhibitor were 
reported in 2017, with a median OS of 13 months [31]. Among 
249 patients in the MAMMOTH study who received therapy after 
becoming refractory to daratumumab or isatuximab, the overall 
response rate (ORR) declined from 31% for the second line of 
treatment to 18% for the sixth [30]. This lack of efficacy high-
lights the urgent need for additional therapies to treat patients 
with advanced RRMM.
1.2. Therapies with new MOAs for RRMM
Several novel drugs with new MOAs have been approved or 
are in development for RRMM, including selective inhibitors of 
nuclear export (selinexor), B-cell maturation antigen (BCMA)- 
directed immunotherapies, and the PDC melflufen [23,32,33]. 
Selinexor is approved in the US in combination with dexa-
methasone to treat patients with RRMM who have received at 
least four prior therapies and who have disease that is refrac-
tory to at least two proteasome inhibitors, two IMiDs, and an 
anti-CD38 mAb [34,35]. Selinexor plus dexamethasone was 
evaluated in the Phase II STORM study in patients with 
RRMM and triple-class refractory disease [34]. In STORM, 
patients (N = 122) had received a median of seven (range, 
3–18) prior treatment regimens, 65 (53%) had high-risk cyto-
genetics, including 32 (26%) with del(17p) [34]. In the primary 
analysis, the ORR was 26% with a median progression-free 
survival (PFS) and median OS of 3.7 months and 8.6 months, 
respectively [34]. Common grade ≥3 adverse events (AEs) with 
selinexor and dexamethasone were thrombocytopenia (59%), 
anemia (44%), fatigue (25%), hyponatremia (22%), and neutro-
penia (21%). Among patients with grade ≥3 thrombocytope-
nia, grade ≥3 bleeding events were observed in 6 patients 
(5%) [34].
Idecabtagene vicleucel (bb2121; ide-cel), an investiga-
tional autologous BCMA chimeric antigen receptor (CAR) 
T-cell therapy [36], was evaluated in a Phase I study (CRB- 
401) in 33 patients with RRMM who had received at least 
three prior therapies, including an IMiD, a proteasome inhi-
bitor, or both, and in the expansion phase, patients had 
prior daratumumab, and were refractory to their most 
recent therapy [36]. The ORR was 85% and, with a median 
follow-up of 11.3 months (range, 6.2–22.8), the median PFS 
was 11.8 months [36]. Common grade 3/4 AEs with ide-cel 
were anemia (45%/0%), leukopenia (18%/39%), thrombocy-
topenia (15%/30%), and neutropenia (6%/79%) [36]. Grade 
≥3 cytokine release syndrome and neurotoxicity events 
were reported in 6% (n = 2) and 3% (n = 1) of patients 
treated with ide-cel, respectively, and no grade 4 cytokine 
release syndrome was reported [36]. One death (cardiopul-
monary arrest) considered to be unrelated to treatment was 
reported [36]. Results from the CRB-401 study suggest ide- 
cel is safe and yields high response rates in patients with 
RRMM with at least three prior therapies [36]. KArMMA, an 
ongoing, multicenter Phase II study of ide-cel, examining 
the efficacy and safety of a 150-to-450x106 dose of ide-cel, 
has enrolled 128 patients with triple-exposed RRMM [37]. 
After a median follow up of 11.3 months, the study has met 
its primary endpoint, with an ORR of 73.4% [37]. The next- 
generation anti-BCMA CAR T–cell therapy bb21217, which 
adds a phosphoinositide 3-kinase inhibitor to enrich for 
Article Highlights
● Patients with multiple myeloma that are refractory to multiple agents 
with distinct mechanisms of action have limited treatment options, 
face universally poor outcomes, and are in urgent need of novel 
therapeutics.
● Melphalan flufenamide (melflufen) is a first-in-class peptide-drug 
conjugate (PDC) that targets aminopeptidases and rapidly releases 
alkylating agents into tumor cells.
● Melflufen has demonstrated potent cytotoxic activity in vitro in 
multiple myeloma cells, including those with resistance to other 
treatments (e.g., immunomodulatory drugs, proteasome inhibitors, 
and alkylators), and induces irreversible DNA damage and apoptosis.
● Melflufen in combination with dexamethasone has demonstrated 
clinically meaningful efficacy in patients with heavily pretreated 
relapsed/refractory multiple myeloma, including in patients with 
triple-class–refractory disease and those with extramedullary disease.
● Melflufen has demonstrated a well-established safety profile with 
clinically manageable hematologic adverse events being most 
common.
Box 1. Drug summary.
Drug name (generic) Melphalan flufenamide (melflufen)
Phase (for indication under discussion) I, II, and III study
Indication (specific to discussion) Multiple myeloma
Pharmacology description/mechanism of 
action
Peptide-drug conjugate
Route of administration 40 mg IV (on day 1 of each 28-day 
cycle)
Chemical formula C24H30Cl2FN3O3
Pivotal trial HORIZON [16]
IV: intravenous. 
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memory-like T cells, is currently in Phase I clinical stu-
dies [38].
The anti-BCMA antibody-drug conjugate belantamab 
mafodotin (GSK857916) was evaluated in a two-arm, rando-
mized, open-label, Phase II study in patients with RRMM who 
had received three or more prior lines of therapy and who 
were refractory to IMiDs, proteasome inhibitors, and refrac-
tory or intolerant (or both) to an anti-CD38 mAb (DREAMM-2) 
[33]. In DREAMM-2, 196 patients were randomized to receive 
2.5 mg/kg (n = 97) or 3.4 mg/kg (n = 99) doses of belanta-
mab mafodotin [33]. As of the 21 June 2019 data cutoff, ORR 
was 31% and 34% in patients treated with the 2.5-mg/kg and 
3.4-mg/kg dose of belantamab mafodotin, respectively. 
Median PFS was 2.9 months and 4.9 months at the 2.5-mg/ 
kg and 3.4-mg/kg dose of belantamab mafodotin, respec-
tively, and survival data were not mature at the data cutoff 
[33]. Common grade 3/4 AEs in the safety population receiv-
ing the 2.5-mg/kg (n = 95) or 3.4-mg/kg (n = 99) dose of 
belantamab mafodotin, were keratopathy (27% and 21%), 
thrombocytopenia (20% and 33%), and anemia (20% and 
25%) [33]. Serious AEs (SAEs) occurred in 40% and 47% of 
patients treated at the 2.5-mg/kg and 3.4-mg/kg dose of 
belantamab mafodotin, respectively, and two treatment- 
related deaths were reported (1 with the 2.5-mg/kg dose 
[due to sepsis] and 1 with the 3.4-mg/kg dose [due to 
hemophagocytic lymphohistiocytosis]) [33]. In DREAMM-2, 
belantamab mafodotin showed clinically meaningful activity 
consistent with that of previously reported data for the 
DREAMM-1 study. Despite higher-risk patients being more 
numerous in DREAMM-2 than in DREAMM-1, the AE profile 
of DREAMM-2 was acceptable and no new safety signals 
were identified [33,39].
1.3. Emerging agents
Bispecific antibodies are still in the earliest stages of develop-
ment, yet they have the potential to be a viable treatment 
option for patients with RRMM. Clinical data have been 
reported for three BCMA:CD3 bispecific agents: AMG 420, 
CC-93269, and REGN5458 [40–42]. In a first-in-human study 
of AMG 420, among 42 patients who received 400 micro-
grams/day of AMG 420, the ORR was 70%, with only one 
patient (2.4%) being treated for grade 3 cytokine release 
syndrome [43]. In a first-in-human study of CC-93269, 12 
patients were treated with at least 6 mg of CC-93269 every 
week or biweekly which resulted in an ORR of 83.3% [44]. In 
this study, one of 19 patients (5.3%) died of cytokine release 
syndrome. A Phase 1 study of REGN5458 used a similar dosing 
regimen (6 mg every week/biweekly) in 4 patients, 75% of 
whom responded [45]. No cases of grade ≥3 CRS were 
reported in seven patients.
Figure 1. Clinical structure of melflufen hydrochloride and its metabolites melphalan and desethylmelflufen.
Figure reproduced with permission from Schjesvold F, Robak P, Pour L, et al. Future Oncol. 2020;16(11):631–41 [32]. 
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2. Melflufen
2.1. Mechanism of action
Melflufen is a first-in-class peptide-drug conjugate (PDC) that 
targets aminopeptidases and rapidly releases alkylating agents 
into tumor cells (Figure 1) [17,46]. Peptidases are expressed in 
several types of cancer cells, including those of MM [47–49]. 
Melflufen is rapidly taken up by myeloma cells due to its high 
lipophilicity [17,46]. Once inside the myeloma cell, the activity 
of melflufen is dependent on its immediate hydrolysis by 
peptidases, which unleashes its more hydrophilic alkylator 
payloads that remain entrapped within the cell (Figure 2) 
[17,50,51]. Melflufen rapidly induces irreversible DNA damage 
and apoptosis via an alkylator-like, yet distinct mechanism of 
cytotoxicity that is independent of p53 function in MM cells 
[46,52,53]. Melflufen is 50-fold more potent than melphalan in 
MM cells in vitro because the combined effects of its high 
lipophilicity and intracellular binding to aminopeptidases 
results in increased intracellular alkylator exposure with mel-
flufen (vs melphalan) [17,46,54]. Melflufen also has significant 
anti-myeloma activity, comparing favorably with melphalan 
in vivo with traditional xenografts [46] or genetically engi-
neered transgenic models of the disease [55].
2.2. Overview of clinical trials
2.2.1. O-12-M1
O-12-M1 was a Phase I/II study to establish the dose and dosing 
schedule of melflufen in combination with dexamethasone and 
to investigate initial treatment responses in patients with RRMM 
with disease refractory to the last line of therapy [18]. The Phase 
I portion of the study originally employed a 21-day cycle with no 
dose-limiting toxicities occurring at the melflufen 40-mg dose 
level. However, in the Phase II dose-expansion portion of the 
study, the cycle length was increased from 21 to 28 days, provid-
ing additional time for recovery of the platelet and neutrophil 
counts, reducing the need for cycle delays and dose modifica-
tions, and allowing patients to remain on treatment longer [18]. 
Thus, O-12-M1 identified the maximum tolerated dose of mel-
flufen of 40 mg and the minimum acceptable cycle length of 
28 days in combination with dexamethasone as the recom-
mended regimen for further evaluation in patients with RRMM 
[18]. Prior to the O-12-M1, a study of melflufen plus dexametha-
sone on patients with solid tumors demonstrated that the phar-
macokinetic parameters of melflufen were not significantly 
influenced by weight, thus, a fixed dosing schedule was used in 
subsequent studies [56].
Figure 2. Melflufen mechanism of action.
Melflufen targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Peptidases are expressed in several types of cancer cells, including those of MM. Melflufen is 
rapidly taken up by mylema cells due to its high lipophilicity. Once inside the multiple myeloma cell, the activity of melflufen is dependent on its immediate hydrolysis by peptidases, which 
unleashes its more hydrophilic alkylator payloads that remain entrapped within the cell. 
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In 45 patients treated in the Phase II portion of O-12-M1, 
melflufen and dexamethasone demonstrated durable 
responses with a manageable safety profile. Patients had 
received a median of four prior lines of therapy (interquartile 
range, 3–5), 24 (53%) had received prior alkylator therapy, 30 
(67%) were double-refractory (proteasome inhibitor and IMiD), 
nine (20%) had International Staging System (ISS) stage III 
disease, 20 (44%) had high-risk cytogenetics by fluorescence 
in situ hybridization, and 26 (58%) had a prior autologous 
stem cell transplant [18]. ORR by investigator assessment was 
31%, including 5 patients who achieved very good partial 
response (VGPR) and 9 who achieved partial response (PR), 
and the clinical benefit rate (CBR; ≥minimal response) was 
49% (Table 1) [18]. After a median follow-up of 27.9 months, 
the median duration of response (DOR) was 8.4 months, and 
median PFS and OS were 5.7 months and 20.7 months, respec-
tively (Table 1) [18]. The most common AEs (all grades), 
regardless of relationship to study drug, included thrombocy-
topenia (73%), neutropenia (69%), anemia (64%), pyrexia 
(40%), and asthenia (31%) (Table 2) [18]. Grade ≥3 AEs, regard-
less of cause, occurred in 91% of patients, and melflufen- 
related grade ≥3 AEs occurred in 58%. The most common 
melflufen-related grade 3/4 AEs were thrombocytopenia 
(58%) and neutropenia (58%) [18]. Overall, seven bleeding 
events, all grade 1, were reported in association with grade 4 
thrombocytopenia [18]. Treatment-emergent SAEs were 
reported in 38% of patients, with pneumonia being the most 
common (11%) and febrile neutropenia being observed in 4% 
of patients [18]. Overall, four deaths occurred in patients with 
rapidly progressing disease within 30 days of the last dose of 
melflufen, two of which (neutropenic sepsis and Escherichia 
coli sepsis) were assessed as possibly treatment related.
2.2.2. HORIZON
HORIZON (OP-106) is a pivotal, single-arm, multicenter, Phase 
II study evaluating the efficacy and safety of melflufen and 
dexamethasone in heavily pretreated and poor-risk patients 
with RRMM refractory to pomalidomide or an anti-CD38 mAb, 
or both [19]. In an interim analysis of HORIZON, melflufen and 
dexamethasone had efficacy and was generally safe and well 
tolerated in 154 patients with RRMM who had exhausted most 
salvage therapy options (data cutoff 1 October 2019) [19]. 
Patients had a median age of 64.5 years (range, 35–86) and 
had received a median of five prior lines of therapy (range, 
2–12) with 83% of patients having received prior alkylator 
therapy; 32% had ISS stage III disease, 38% had high-risk 
cytogenetics, 32% had extramedullary disease, 71% had triple- 
class refractory disease, and 69% had received ≥1 prior auto-
logous stem cell transplant. Among 125 efficacy-evaluable 
patients, the ORR by investigator assessment was 29% (1 
stringent complete response [CR], 12 VGPR, and 23 PR) and 
the CBR was 44% (Table 1) [19]. The median DOR was 
4.4 months, median PFS was 4.2 months, and median OS 
was 11.6 months [19]. In patients with triple-class refractory 
disease and extramedullary disease, ORR was 24% and 24%, 
median DOR was 7.5 and 5.1 months, median PFS was 4.0 and 
3.0 months, and median OS was 11.3 and 8.1 months, respec-
tively. In the overall population (N = 154), 97% of patients 
experienced a treatment-emergent AE and 85% experienced 
a grade 3 or 4 treatment-emergent AE. The most common 
(≥20%) grade 3/4 treatment-emergent AEs were thrombocy-
topenia (21%/48%), neutropenia (31%/35%), and anemia 
(36%/1%) [19]. In addition, febrile neutropenia was also 
observed (4%/1%), and the incidence of nonhematologic AEs 
was low [19]. As of the interim analysis data cutoff, five 
patients (3%) have died due to treatment-emergent AEs and 
none of these deaths were treatment related [19]. These find-
ings are highly encouraging because patients in whom lenali-
domide- and PI-based treatments have failed have limited 
remaining effective treatment options [28,30].
2.2.3. ANCHOR
ANCHOR (OP-104) is a Phase I/II study evaluating the safety 
and efficacy of melflufen and dexamethasone in triplet com-
binations in patients with RRMM [20]. Preliminary data from 
ANCHOR showed activity of melflufen and dexamethasone 
with daratumumab or bortezomib. As of the data cutoff 
(8 October 2019), 33 patients had been treated with melflufen 
(6 with a 30-mg dose; 27 with a 40-mg dose) in combination 
with daratumumab and dexamethasone, with a median treat-
ment duration of 6.2 months (range, 0.9–18.0) [20]. Patients 
had a median of 2.5 (range, 1–3) and 2 (range, 1–4) prior lines 
of therapy in the 30-mg and 40-mg melflufen treatment 
groups, respectively [20]. In addition, 83% and 89% of patients 
had received prior alkylator therapy in the 30-mg and 40-mg 
melflufen treatment groups, respectively. However, patients 
must have been naïve to prior anti-CD38 mAb therapy [20]. 
The ORR (≥PR) was 76% (1 stringent CR, 11 VGPR, and 13 PR), 
the CBR was 79%, and median PFS was 14.3 months [20]. At 
data cutoff, six patients had been treated with melflufen (3 
with 30 mg; 3 with 40 mg) plus dexamethasone and bortezo-
mib, with a median treatment duration of 9.3 months. Patients 
had a median of 2.5 prior lines of therapy (range, 2–4), and no 
patient had achieved CR in any previous line [20]. Further, all 
patients had previously been exposed to a proteasome inhi-
bitor, but could not have been refractory to proteasome inhi-
bitors, and 5 patients had received prior alkylator therapy [20]. 
ORR was 67%, and the CBR was 83% in these six patients, 
including two patients each who achieved VGPR and PR [20]. 
No dose-limiting toxicities were observed at any of the eval-
uated dose levels during dose-escalation with either daratu-
mumab or bortezomib combinations. Among patients who 
received melflufen 30 mg (n = 6) and 40 mg (n = 27) in the 
Table 2. Most common treatment-emergent AEs with melflufen and dexa-
methasone in O-12-M1 [18].
Adverse events, n (%)
Melflufen in combination with dexamethasone 
(n = 45)
All grades Grade 3–4 Grade 5
Thrombocytopenia 33 (73) 28 (62) 0 (0)
Neutropenia 31(69) 27 (60) 1 (2)
Anemia 29 (64) 20 (44) 0 (0)
Pyrexia 18 (40) 2 (4) 0 (0)
Asthenia 14 (31) 3 (7) 0 (0)
Fatigue 13 (29) 2 (4) 0 (0)
Nausea 12 (27) 0 (0) 0 (0)
Diarrhea 11 (24) 1 (2) 0 (0)
Pneumonia* 7 (16) 3 (7) 2 (4)
*There was one case each of a grade 3 and a grade 5 pneumonia overlapping 
with a grade 4 neutropenia. 
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daratumumab combination group, the most common grade 
3/4 treatment-related AEs (≥2 patients) were neutropenia 
(83%/56%), thrombocytopenia (50%/67%), and anemia (50%/ 
7%) [20]. Six patients in this group experienced treatment- 
related SAEs, including febrile neutropenia (n = 2), abdominal 
pain, pancytopenia, pyrexia, respiratory failure, sepsis, and 
upper respiratory tract infection (n = 1 each) [20]. In the six 
patients in the bortezomib combination group, grade 3/4 
treatment-related AEs of thrombocytopenia (n = 5), neutrope-
nia (n = 3), anemia (n = 1), and pneumonia (n = 1) were 
observed and one patient experienced treatment-related 
SAEs (neutropenia and pneumonia) [20].
2.3. Safety and tolerability
Patients with RRMM have depleted bone marrow reserves due 
to the disease as well as side effects of prior therapy, and 
cytopenias are common [58]. Despite cytopenias being com-
mon with melflufen, particularly thrombocytopenia, they are 
clinically manageable with a low incidence of bleeding events 
[18]. However, it is important to vigilantly monitor cytopenias 
with melflufen and to provide appropriate management and 
supportive care for platelet count recovery including dose 
reductions, growth factor support, and platelet transfusions 
[59,60]. Despite working through an alkylator-dependent 
mechanism, melflufen does not appear to cause alopecia 
and incidence of mucositis is low, primarily grade 1/2 [18].
2.4. Regulatory status
Melflufen is an investigational drug and has been granted 
orphan drug designation in the United States and Europe 
[61]. The US Food and Drug Administration granted priority 
review to the New Drug Application for melflufen in combina-
tion with dexamethasone for the treatment of adult patients 
with triple-class refractory MM, with a target date for review of 
the New Drug Application set for February 28, 2021 [62].
3. Conclusions
To date, melflufen has demonstrated durable responses and 
a manageable safety profile in patients with RRMM. 
Treatment-related AEs associated with melflufen and dexa-
methasone are primarily hematologic, and rates of nonhema-
tologic AEs are low. Based on the encouraging activity and 
acceptable safety profile of melflufen in RRMM, the rando-
mized, head-to-head, superiority, open-label, global, Phase III 
OCEAN (OP-103) study is evaluating the efficacy and safety of 
melflufen plus dexamethasone versus pomalidomide plus dex-
amethasone in patients with RRMM who received two to four 
prior therapies including lenalidomide within 18 months and 
are refractory to the last line of therapy (Table 1) [32]. Top-line 
results for OCEAN are expected in the first half of 2021 [32].
4. Expert opinion
Current standards in the treatment of MM include combina-
tions of IMIDs, proteasome inhibitors, corticoids, and mAbs in 
frontline and early relapse treatment settings. As 
a consequence, there is a growing need for novel agents 
with alternative MOAs for patients with RRMM who are refrac-
tory to IMiDs, proteasome inhibitors, and anti-CD38 mAbs. 
A major proportion of patients who do not enjoy 
a prolonged response to frontline treatment are expected to 
be triple-class refractory early in the course of disease, as 
triplet or quadruplet combinations of effective agents are 
used both upfront and at first relapse. In contrast, the role of 
alkylating agents in early MM is becoming relatively limited, 
except for the use of high dose melphalan in younger 
patients. The encouraging efficacy of melflufen and dexa-
methasone in RRMM suggests this combination will provide 
an important option and translate successfully to real-world 
practice, strengthened by the convenience of a monthly infu-
sion schedule [63]. Specifically, the activity of melflufen in the 
triple-class refractory patient population is promising, given 
the otherwise poor prognosis in these patients. Melflufen as 
a single agent appears to be not only effective in patients not 
exposed to alkylating agents but also to overcome prior che-
motherapy resistance. Its response rate in extramedullary dis-
ease is of interest too, as extramedullary disease represents 
a major issue in the context of aggressive MM progression. In 
addition to its distinct MOA, melflufen has a manageable and 
a toxicity profile nonoverlapping with alternative agents. 
Although oral drugs are preferred options at early stages of 
the disease, gastrointestinal toxicity, mainly diarrhea and 
malabsorption, are present in a relevant proportion exposed 
to lenalidomide and pomalidomide. Patients with a prior his-
tory of gastrointestinal toxicity may not be ideal candidates for 
selinexor therapy. Similarly, panobinostat may have a limited 
role due to toxicity issues. Others may have limited options by 
virtue of prior treatment-related toxicity such as peripheral 
neuropathy, both features melflufen does not share. 
Melflufen may also be more suitable than belantamab mafo-
dotin and other investigational agents for a subset of patients 
given its otherwise limited nonhematologic toxicity, including 
absence of alopecia and minimal mucositis as well as low rates 
of infection, an especially important consideration in the cur-
rent era. Its predictable hematologic toxicity and potency may 
further position melflufen as a preferred option for bridging 
therapy for other important emerging treatment strategies 
such as CAR T-cell therapy. Moreover, significantly greater 
clinical activity is anticipated from the combination of melflu-
fen with proteasome inhibitors or mAbs in a less advanced 
setting, with preliminary data strongly supporting this [20]. 
Furthermore, if the efficacy and safety of melflufen in combi-
nation with daratumumab is confirmed, melflufen could also 
be a potential partner for immunotherapeutic agents such as 
bispecific antibodies in the near future, providing an ideal 
combination of drugs with high individual efficacy, MOAs 
not exhausted in previous treatment lines, and a potentially 
relatively favorable safety profile.
The remarkable progress observed in MM treatment may 
be able to provide a very prolonged disease-free period for 
a significant proportion of patients or even cure some of them. 
However, it is expected that most individuals still relapsing will 
present more aggressive and resistant disease. We need to 
increase our armamentarium to face the needs of such indivi-
duals with drugs and combinations with alternative MOAs. 
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Melflufen may become a preferred choice either in combina-
tion with dexamethasone only or with third agents.
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